FLT3 and acute myeloid leukemia: Several studies employing a range of different FLT3 inhibitors such as SKLB-677 [130], PKC412, AG1296, CEP-701 [79], sorafenib and quizartinib [48], have shown them to be effective at targeting β-catenin activity/stability and/or AML LSCs whilst sparing normal HSC.